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Kidney Transplantation: Only for the Well-to-Do?
JENNIFER M. SMITH*
"To have to worry about how you're going to pay for transplant medica-
tions 36 months down the road is a shame."'
INTRODUCTION
The world of organ transplantation remains a wealthy one, espe-
cially in the United States. Well-to-do Americans who need an organ
transplant travel to Third World countries to get an organ from some
poor, living person, then travel back to the United States for their con-
tinued post-operative care.2 This is especially true for kidney trans-
plantations, which involve the solid organ most in demand.3
Increasingly, transplant professionals desperately push for more
solutions to overcome the organ transplant shortage that exists in the
United States because of the increase in mortality occurring due to
© Jennifer M. Smith, 2008.
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for a kidney transplant and, thus, unable to afford a better quality of life.
1. Deborah Shelton, The Transplant Gap Keeps More Blacks Waiting for Kidneys,
CHI. TRIB., July 8, 2008 (quoting Willa Lang, president and chief executive officer of
the National Kidney Foundation of Illinois), available at http://www.donatelifeillinois.
org/donatelife/news/Tribune07-08-08.pdf.
2. Vanessa Chandis, Addressing a Dire Situation: A Multi-Faceted Approach to the
Kidney Shortage, 27 U. PA. J. INT'L ECON. L. 205, 218 (2006) (commenting that kidneys
come from people who live in poorer countries, such as India and South America, and
are transplanted to people in richer countries, such as the United States).
3. See INT'L ASS'N FOR ORGAN DONATION, UNDERSTANDING: STATISTICs/FACTS, http://
iaod.org/understanding-organ-donation.htm (last visited Mar. 9, 2009) (reporting that
4066 people died in the United States in 2006 while waiting for a kidney and 1605
people died waiting for a liver).
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lack of a kidney transplant.4 Historically, Americans have objected to
the outright sale of human organs because many fear that selling
human organs will result in the exploitation of the poor.' More
recently, however, some scholars have suggested that exploitation of
the poor is a ridiculous paternalistic concern that prevents poor peo-
ple from increasing their wealth by selling their body parts as living
donors.6
4. See, e.g., 7 ADVANCES IN BIOETHICS: THE ETHICS OF ORGAN TRANSPLANTATION
(Wayne Shelton & John Balint eds., 2001); MARK CHERRY, KIDNEY FOR SALE BY OWNER:
HUMAN ORGANS, TRANSPLANTATION, AND THE MARKET (2005); BARRY R. SCHALLER,
UNDERSTANDING BIOETHICS AND THE LAW: THE PROMISES AND PERILS OF THE BRAVE NEW
WORLD OF BIOTECHNOLOGY (2008); THE ETHICS OF ORGAN TRANSPLANTS: THE CURRENT
DEBATE (Arthur L. Caplan & Daniel H. Coelho eds., 1998); ROBERT M. VEATCH,
TRANSPLANTATION ETHICS (2000); Gloria J. Banks, Legal & Ethical Safeguards: Protection
of Society's Most Vulnerable Participants in a Commercialized Organ Transplantation
System, 21 AM. J.L. & MED. 45 (1995); E.A. Friedman & A.L. Friedman, Payment for
Donor Kidneys: Pros and Cons, 69 KIDNEY INT'L 960 (2006), available at http://www.
nature.com/ki/journal/v69/n6/full/5000262a.html; Alexandra Glazier & Scott
Sasjack, Should It Be Illicit to Solicit? A Legal Analysis of Policy Options to Regulate
Solicitation of Organs for Transplant, 17 HEALTH MATRIX 63 (2007); Michele Goodwin,
The Body Market: Race Politics & Private Ordering, 49 ARIz. L. REV. 599 (2007); Richard
Schwindt & Aidan R. Vining, Proposal for a Future Delivery Market for Transplant
Organs, 11 J. HEALTH POL. POL'Y & L. 483 (1987).
5. See CHERRY, supra note 4, at 8-9, 76 (stating that one social concern over
commercialization is that "cash payments will attract primarily poor and low-income
segments of the population, including racial minorities, who will disproportionately
bear the health care complications of being vendors, as well as being increasingly
subjected to exploitation"); Laura Meckler, Kidney Shortage Inspires a Radical Idea:
Organ Sales, WALL ST. J., Nov. 13, 2007, at D1, available at http://online.wsj.com/
public/article-print/SB119490273908090431.html (reporting that Francis
Delmonico, a transplant surgeon, fears that organ sales "would attract the poor,
vulnerable and unhealthy"); Todd Zwillich, Analysis: Cash Payments for Organs?,
UNITED PRESS INT'L, Apr. 21, 2006, available at http://www.accessmylibrary.com/
coms2/summary_0286-14963194 ITM (reporting that Robert Veatch, who opposed
cash payments for organs for decades because of the potential to exploit poor people,
is now calling for experimentation with cash payments for organs because so many
people are dying as a result of the organ shortage).
6. See William Barnett II et al., A Free Market in Kidneys: Efficient and Equitable, 5
INDEP. REV. 373, 374 (2001), available at http://www.independent.org/pdf/tir/tir 05
3_barnett.pdf ("[T]he prohibition against the purchase and sale of kidneys forecloses
[poor people from converting their physical human capital into a more valuable form
of wealth], insofar as it involves the sale of a kidney. It effectively prevents [poor
people] from making choices that they believe would increase their well-being. The
current prohibition is paternalistic, and as such it is dehumanizing. Adults, because
they are poor, are treated as if they are incapable of making decisions in their own best
interest. Rather, government officials make one-size-fits-all decisions for them, with no
knowledge whatsoever-much less personal knowledge-of them as individuals or of
334
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Even if Americans put aside their reservations about the potential
exploitation of the poor and embrace this new paradigm shift, which
would allow poor citizens to sell their body parts, the poor working
class who need kidney transplants-and in fact who would also be the
very ones sought after as living kidney donors-could not afford to be
a kidney recipient.7 This is because they would not be able to afford
the lifetime cost of the immunosuppressive medication (or anti-rejec-
tion drugs) necessary to ensure that their bodies do not reject the
"new" kidney.'
As it now stands, the federal government pays the costs to main-
tain individuals on dialysis for life and covers eighty percent of the
cost of immunosuppressive drug therapy for Medicare kidney recipi-
ents for a life.9 However, the government only covers the cost of immu-
their individual situations and values." (citation and footnote omitted)); AP Monaco,
Rewards for Organ Donation: The Time Has Come, 69 KIDNEY INT'L 955 (2006), available
at http://www.nature.com/ki/journal/v69/n6/full/5000281a.html (noting that
government efforts to reward organ donors may be viewed as implementing a policy
that directly exploits the poor); Eugene Volokh, Medical Self-Defense, Prohibited
Experimental Therapies, and Payment for Organs, 120 HARV. L. REV. 1813, 1842-43
(2007) (citing Russell Korobkin, Buying and Selling Human Tissues for Stem Cell
Research, 49 ARiz. L. REV 45 (2007)) (noting that if an organ provider believed that
money was worth the small health risk, the government's interest in protecting the
donor against the temptation should not trump the recipient's medical self-defense
right).
7. But cf. Barnett et al., supra note 6 (concluding that allowing the sale of human
organs in the United States would solve the issues surrounding the organ shortage and
the wealthy and poor would have access to kidneys, but failing to address the costs
associated with maintenance of transplanted kidneys).
8. See discussion infra Part 1.
9. Alexander S. Goldfarb-Rumyantzev et al., Role of Socioeconomic Status in Kidney
Transplant Outcome, 1 CLINICAL J. Am. Soc'Y NEPHROLOGY 313 (2006) ("Medicare
beneficiaries who are eligible to receive the immunosuppressive medication coverage
must still pay 20% of the cost of these medications as Medicare covers only 80% of the
total cost."); see also Elisa J. Gordon, The Ethics of Medicare Policy: Increasing Transplant
Access and Survival, 55 DEPAUL L. REV. 1045, 1047 (2006) (finding that the twenty
percent co-pay that organ recipients must pay during the first thirty-six months places
the transplanted kidney at risk of rejection); Bertram L. Kasiske et al., Payment for
Immunosuppression After Organ Transplantation, 283 JAMA 2445 (2000) (advocating
that "Medicare should cover the cost of all immunosuppressive therapy for all solid
organ transplant recipients who cannot afford to pay" because currently "Medicare
covers most transplantation procedures in the United States, but ends coverage for
outpatient immunosuppressive medications after 36 months"); NATCO, POSITION
STATEMENT: MEDICARE COVERAGE FOR IMMUNOSUPPRESSIVE DRUGS (2006), available at
http://www.natcol .org/public-policy/documents/MedicareDrugCoverage.pdf ("[T]he
20% co-pay can be prohibitive and lead to nonadherence with the prescribed
medication regime, potential organ dysfunction, organ loss or even death.").
20091 335
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nosuppressive drug therapy for individuals under sixty-five and not
otherwise disabled for three years after a successful kidney trans-
plant.1 ° Because these post-transplant anti-rejection medications are
so expensive, many people with low or fixed incomes do not meet the
financial criteria necessary to qualify to receive a kidney transplant.
This is because they will not be able to pay for the cost of maintaining
the transplant after government assistance terminates.
Congress has introduced legislation that purports to remedy this
situation by providing that the government will pay eighty percent of
the cost for the post-transplant medications for life.' But unless this
bill passes and other needed changes are made, kidney transplantation
remains an option primarily for the well-to-do.
I. CASE STUDIES
Jessica and Emily's stories are not unique. Both need a kidney
transplant; neither can afford one.
Jessica is a twenty-year-old Florida resident whose transplanted
kidney "shriveled up" soon after she turned eighteen.' 2 Since that
time, she has spent three hours a day three days a week on kidney
dialysis just to stay alive. 3 There is no cost for kidney dialysis for
Jessica; the government pays it all.
Jessica received her first kidney transplant at the age of twelve.' 4
She appeared to be a model kidney-transplant patient; she is a competi-
tive swimmer, a surfer, and a lifeguard.' 5 When Jessica received her
donated kidney eight years ago, she was still a minor. The government
paid for the kidney transplant, as well as the immunosuppressive medi-
cations to keep the transplanted kidney functioning.' 6
But when the kidney failed soon after she turned eighteen, Jessica
had other concerns to worry about. Although the government would
pay for the cost of the kidney transplant for an adult, the government's
10. Gordon, supra note 9, at 1052-53 ("Based on Medicare policy, patients (who
are not disabled or age sixty-five and older) are responsible for covering twenty percent
of the costs of immunosuppressive medications for three years and the full costs
thereafter.").
11. See discussion infra Part II.
12. Harry Wessel, Struggles Don't End with Transplant, ORLANDO SENTINEL, Feb. 3,
2008, at Al.
13. Id.
14. Id.
15. Id.
16. Id.
336 [Vol. 31:333
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post-transplant help with the immunosuppressive medications was sig-
nificantly curtailed because Jessica was no longer a minor.
17
Now she has to meet the financial criteria to qualify for a kid-
ney."8 Jessica is unemployed and supports herself with monthly disa-
bility checks.19 Because the transplant center determined that she
would not be able to afford the long-term care of the donated kidney, it
notified her that it was removing her name from the kidney-recipient
waiting list.2 °
Jessica was disappointed. The average wait in the United States
for a kidney is about five years, 21 but in central Florida the wait is
approximately one year.22 With a new kidney, Jessica's life would be
significantly improved, but on dialysis, she remains chronically ill.
2 3
Jessica has several other medical problems-problems involving
her heart, liver, vascular system, and she even had a massive stroke.24
Yet, she was not removed from the kidney transplant waiting list
because of medical issues. Rather, she was involuntarily removed
from the list because she did not meet the financial criteria to receive a
17. Id. ("Medicare does not have a three-year limit for minors, but those who have
had coverage for at least three years lose it once they turn 18."); Lisa M. Willoughby et
al., Health Insurance Considerations for Adolescent Transplant Recipients as They
Transition to Adulthood, 11 PEDIATRIC TRANSPLANTATION 127 (2007) ("It is well-
recognized that there is insufficient healthcare coverage in the general adolescent
population, especially during the transition period into adulthood. The age that this
transition occurs is between 18 and 23 [years], depending on whether insurance is
provided by the state (Medicaid or the State Children's Health Insurance Program),
Medicare or a private health plan.").
18. See, e.g., Kidney Transplant Program, Univ. of S. Cal., Financial
Considerations, http://usckidneytransplant.org/financialconsiderations.html (last
visited Mar. 17, 2009) ("Costs related to transplant include evaluation and testing,
transplant surgery and hospitalization, follow-up care and medication.").
19. See Wessel, supra note 12, at Al.
20. Id.
21. Megan Shaughnessy, A Different Approach to Kidney Allocation in the United
States, 36 DIALYSIS & TRANSPLANTATION 230, 230 (2007) (noting that the wait for a
kidney sometimes is as long as ten years); Laura Neergaard, Therapy Helps Hard-to-
Transplant Get a New Kidney, WASH. TIMES, Oct. 14, 2008 (reporting that the wait for a
kidney can be four to five years); Posting of Sally Satel to The Huffington Post, http://
www.huffingtonpost.com/sally-satel/who-wants-to-be-a-kidney- b-49910.html (May
29, 2007, 21:32 EST) (reporting the average wait for a kidney is five years, but in 2010
the wait may be as long as ten years).
22. See Wessel, supra note 12, at Al.
23. Rebecca P. Winsett et al., Kidney Transplantation, in ORGAN TRANSPLANTATION:
CONCEPTS, ISSUES, PRACTICE, AND OUTCOMES (2002), http://www.medscape.com/
viewarticle/443490print ("[P]atients choose the option of transplantation out of a
desire for more normalcy in their lives.").
24. See Wessel, supra note 12, at Al.
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kidney transplant; she cannot afford the deductibles and co-pays asso-
ciated with a transplant.25
Emily's story is a bit different. She is a twenty-seven year old stu-
dent in Illinois.26 She has been on kidney dialysis for years, but over
time, dialysis became less effective.27 While most people waiting for a
kidney do all they can to get to the top of the waiting list, even going
abroad for a kidney transplant, Emily has delayed trying to get a trans-
plant for several years because she does not believe that she can afford
the post-transplant anti-rejection drugs.2 8 Although she began the pro-
cess of obtaining an evaluation for a transplant, she remains torn-
how will she pay for the immunosuppressive medications that may
average $15,000 annually?29
Jessica and Emily's worries are common in the kidney transplant
world. There are also those who work post-transplant and thus do not
qualify for government assistance who cannot afford the annual cost of
the immunosuppressive drugs. Jessica was removed from the waiting
list and Emily is afraid to join the list because neither has the financial
means to maintain a kidney post-transplant.3° Emily remains on dialy-
sis, but that treatment option makes it more likely that she will not be
able to work.31 Further, the chances of receiving a successful trans-
plant decreases with time.32
So, many potential kidney recipients cannot receive transplants
because they cannot afford the deductibles, co-payments, anti-rejection
medications and other costs associated with a kidney transplant.
These real life scenarios beg the question: is kidney transplantation
only for the well-to-do?
II. COMPREHENSIVE IMMUNOSUPPRESSIVE DRUG COVERAGE FOR KIDNEY
TRANSPLANT PATIENTS ACT OF 2007
Many Americans are living with some form of kidney disease. 33
Years ago, a diagnosis of severe kidney disease or renal disease "sig-
25. Id.
26. Shelton, supra note 1.
27. Id.
28. Id.
29. See infra note 121.
30. Id.; see also Wessel, supra note 12, at Al.
31. Winsett et al., supra note 23 ("The longer patients remain on dialysis, the more
difficult it is to reintroduce the patient to employment.").
32. Neergaard, supra note 21.
33. See, e.g., Erika L. Rager, The Donation of Human Organs and the Evolving
Capacity for Transplantation: Exciting Developments and Future Prospects, 65 N.C. MED.
J. 18 (2004), available at http://www.ncmedicaljournal.com/jan-feb-04/ar010403.pdf
338 [Vol. 31:333
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naled certain death within a short period of time.' 34 Renal disease
occurs when there is a failure of the kidney to properly excrete waste,
which causes subsequent accumulation of urea and other nitrogenous
waste in the blood.35 When kidneys permanently fail to function, it is
called end stage renal disease (ESRD), 36 which is chronic renal disease
that necessitates dialysis or transplantation 37-the two treatment
options for ESRD.38 However, these options are not mutually
exclusive.39
The most common option is dialysis, which is a process that cle-
ans excess potassium from a person's blood.4 ° The government cur-
rently will pay for a lifetime of dialysis, but dialysis leaves the person
chronically ill with a less than adequate quality of life. 41 The preferred
option, transplantation, results in a higher quality of life.42 Patients do
(noting that by the end of 2003 there were over 85,000 people with end stage renal
disease awaiting a transplant in the United States).
34. See COMM. ON NUTRITION SERVS. FOR MEDICARE BENEFICIARIES, INST. OF MED., THE
ROLE OF NUTRITION IN MAINTAINING HEALTH IN THE NATION'S ELDERLY 132 (2000)
[hereinafter THE ROLE OF NUTRITION].
35. See id. at 133.
36. SandraJ. Carnahan, Medicare's Coverage with Study Participation Policy: Clinical
Trials or Tribulations?, 7 YALE J. HEALTH POL'Y L. & ETHICS 229, 234 n.20 (2007).
37. THE ROLE OF NUTRITION, supra note 34, at 133-34 (remarking that ESRD
necessitates treatment by dialysis or transplantation); James F. Blumstein,
Government's Role in Organ Transplantation Policy, in ORGAN TRANSPLANTATION POLICY:
ISSUES AND PROSPECTS 5, 8 (James F. Blumstein & Frank A. Sloan eds., 1989) (noting
that ESRD is life-threatening absent dialysis or transplantation).
38. Paul W. Eggers, Medicare's End Stage Renal Disease Program, 22 HEALTH CARE
FINANCING REV. 55, 55 (2000), available at http://www.cms.hhs.gov/HealthCare
FinancingReview/Downloads/00fallpg55.pdf ("There are two basic treatments
available to persons with ESRD-dialysis and transplantation."); see also Arthur J.
Matas, A Gift of Life Deserves Compensation: How to Increase Living Kidney Donation
with Realistic Incentives, 604 POL'Y ANALYSIS 2, 2 (2007) (noting a third option for
treatment is no treatment, in which case the patient will eventually die).
39. See Matas, supra note 38, at 2 (noting that a patient may begin on dialysis
before receiving a transplant, and if the transplant fails, may go back to dialysis).
40. See Sally L. Satel & Benjamin E. Hippen, When Altruism Is Not Enough: The
Worsening Organ Shortage and What It Means for the Elderly, 15 ELDER L.J. 153, 158
(2007).
41. Laura G. Dooley & Robert S. Gaston, Stumbling Toward Equity: The Role of
Government in Kidney Transplantation, 1998 U. ILL. L. REv. 703, 718 (1998) (noting
that living on dialysis is constantly onerous).
42. R.M. Jindel et al., Noncompliance After Kidney Transplantation: A Systematic
Review, 35 TRANSPLANTATION PROC. 2868, 2868 (2003) ("Patients with a functioning
transplant also have a significantly longer life span than patients on chronic dialysis.");
Matas, supra note 38, at 2 ("[Clompared with dialysis, kidney transplant significantly
prolongs life and improves quality of life.").
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not have to rely upon dialysis to continue living. They have a "new"
kidney to allow them to function and presumably go back to work.
Thus, this is the favored option for ESRD.43 But with a transplant, the
kidney recipient must take immunosuppressive medications faithfully
for the lifetime of the transplant to maintain the "new" kidney or risk
an organ rejection44 and perhaps death.45
Because of the laws surrounding kidney transplants, many peo-
ple-particularly low income individuals-do not have access to kid-
ney transplantation. Therefore, either they find themselves
involuntarily removed from the transplant waiting lists, like Jessica, or
they do not pursue a donated kidney, like Emily, because they know
they will not be able to pay for the maintenance of the kidney when the
government's aid ends.
This is not new information. Indeed, this disparity in access to
kidney transplantation was the impetus behind the Comprehensive
Immunosuppressive Drug Coverage for Kidney Transplant Patients Act
of 2007 (the Transplant Drug Act). 46 This has been introduced in both
the House4 7 and Senate, 4 8-same language in each bill4 9 -and is now
before the Senate's Committee on Finance.5 0 The Transplant Drug Act,
if passed, would provide a lifetime of immunosuppressive medications
to Medicare kidney transplant recipients whose coverage would other-
wise terminate .5  As proposed, it
43. Eggers, supra note 38, at 56 (recognizing transplantation as the optimal
therapy).
44. Id.
45. Marie A. Chisholm et al., Patient Factors Associated with Adherence to
Immunosuppressant Therapy in Renal Transplant Recipients, 62 AM. J. HEALTH-SYS.
PHARMACY 1775, 1776 (2005) (noting that nonadherence to immunosuppressant
therapy may result in "decreased quality of life, increased health care costs, need for
dialysis, morbidity, and mortality"); COMM. ON MEDICARE COVERAGE EXTENSIONS, INST.
OF MED., EXTENDING MEDICARE COVERAGE FOR PREVENTIVE AND OTHER SERVICES 7
(Marilyn J. Field et al. eds., 2000) [hereinafter EXTENDING MEDICARE COVERAGE] (noting
that experience and evidence confirm that transplant patients eventually lose their
grafts due to lack of immunosuppressive therapy, causing them to return to dialysis,
receive another transplant, or die).
46. H.R. 3282, 110th Cong. (2007).
47. Id.
48. S. 2320, 110th Cong. (2007).
49. See Bill Eliminating 3-Year Time Limitation on Medicare Coverage for Kidney
Transplants Introduced in Senate, BNET, Dec. 2007, available at http://findarticles.
com/p/articles/mimOYUG/isjl 2_17/ai n24241935.
50. GovTrack.us, S. 2320: Comprehensive Immunosuppressive Drug Coverage for
Kidney Transplant Patients Act of 2007: Overview, http://www.govtrack.us/congress/
bill.xpd?bill=S110-2320 (last visited Jan. 1, 2009).
51. Id.
340 [Vol. 31:333
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[a]mends SSA title II (Old Age, Survivors and Disability Insurance)
(OASDI) to: (1) continue entitlement to prescription drugs used in
immunosuppressive therapy furnished to an individual who receives a
kidney transplant for which payment is made under Medicare; and (2)
extend Medicare secondary payer requirements for end stage renal dis-
ease (ESRD) beneficiaries.
Amends title XVIII (Medicare) of SSA to apply special rules to kid-
ney transplant recipients receiving additional coverage for immunosup-
pressive drugs. Deems such individual to be enrolled under Medicare
part B. Makes him or her responsible for the full amount of the appli-
cable premiums. Applies deductible and coinsurance requirements to
the provision of such drugs.
Amends the Public Health Service Act, the Employee Retirement
Income Security Act of 1974 (ERISA), and the Internal Revenue Code
to set forth requirements for group health plans to provide coverage of
immunosuppressive drugs for kidney transplant patients.5 2
Medicare's current three year drug coverage entitlement may
appear strict, but from an historical perspective, it has tripled what it
used to be.53 It is encouraging to witness Congress's reception to the
importance of drug coverage entitlement for kidney transplant recipi-
ents because it may signal that Congress will ultimately pass the Trans-
plant Drug Act that is presently before it.
A. Historical Development of Legislation
Before 1965, health care for the aged and needy was sparse. There
were federal and state government programs, helped by local govern-
ments, charities, and community hospitals, but they were not meeting
the health needs of seniors and low income citizens.54 Thus, Congress
passed the Social Security Act Amendments of 1965, simultaneously
creating both Medicare and Medicaid.5 5 Specifically, this legislation
created:
52. GovTrack.us, S. 2320: Comprehensive Immunosuppressive Drug Coverage for
Kidney Transplant Patients Act of 2007: Congressional Research Service Summary, http://
www.govtrack.us/congress/bill.xpd?bill=S1 10-2320&tab=summary (last visited Jan. 1,
2009).
53. See infra note 114.
54. Almanac of Policy Issues, Medicaid, http://www.policyalmanac.org/health/
medicaid.shtml (last visited Jan. 1, 2009); Social Security Online, Social Security
Administration History, http://www.ssa.gov/history/ssa/lbjmedicare1.html (last
visited Jan. 1, 2009).
55. R. A. Rettig, Socioeconomic Impact of the End Stage Renal Disease Program in the
USA. Payment and Quality of Care, 14 NEFROLOGIA 14 (1994), available at http://www.
revistanefrologia.com/mostrarfile.asp?ID=1591 (noting Medicare and Medicaid were
both adopted in 1965); Almanac of Policy Issues, supra note 54; see also EXTENDING
20091
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A hospital insurance program to cover most seniors (Medicare Part
A);
A voluntary supplementary medical insurance program (Medicare
Part B);
An expansion of an existing program to assist seniors with out of
pocket costs, such as premiums, deductibles, co-payments, and
other uncovered costs; and
The Medicaid program to cover families with dependent children,
the blind and disabled.56
Since its enactment, policymakers have been concerned about the
lack of sufficient outpatient prescription drug benefits.5 7 From the
inception, Medicare provided for prescription drugs that were adminis-
tered in the physician's office to ensure doctors did not hospitalize
patients merely for medications." But an outpatient prescription drug
benefit, which was considered for Medicare Part B, was not included
because of the inability to determine the potential costs of such a
benefit.5 9
Under some political pressure to expand Medicare, President Lyn-
don Johnson called for a task force to determine the viability of a pre-
scription drug benefit under the new Medicare program.60 Created in
1967 and operating for twenty months, the task force concluded in
1969 that "a drug insurance program under Medicare is needed by the
elderly, and would be both economically and medically feasible ...
[and] consideration should be given to providing coverage at the outset
MEDICARE COVERAGE, supra note 45, at 15 (finding that Medicare was created to serve
the needs of older Americans who could not pay for health care or obtain private
insurance, and Medicaid was created to provide health insurance for low income
individuals, mainly poor mothers with children and low-income disabled).
56. Almanac of Policy Issues, supra note 54.
57. JENNIFER O'SULLIVAN, MEDICARE PRESCRIPTION DRUG COVERAGE FOR BENEFICIARIES:
BACKGROUND AND ISSUES (2003), available at http://www.house.gov/towns/pdf/
prescriptiondrugs.pdf ("The absence of an adequate prescription drug benefit has
been of concern to policymakers since the enactment of Medicare in 1965.").
58. Thomas R. Oliver et al., A Political History of Medicare and Prescription Drug
Coverage: Missed Opportunities and Muddled Outcomes, 82 MILBANK Q. 283, 291-92
(2004), available at http://www.allacademic.com//meta/p-mla-apa-researchcitation
/0/6/1/7/6/pages61760/p6l760-1.php.
59. Id. at 291 ("[Tjhe outpatient prescription drug benefit for Part B was dropped
on the grounds of unpredictable and potentially high costs." (citation and internal
quotation marks omitted)).
60. Id. at 293 ("In May 1967 [U.S. Department of Health, Education and Welfare]
Secretary John Gardner established the Task Force of Prescription Drugs in response
to a directive from President Johnson to undertake immediately a comprehensive
study of the problems of including the cost of prescription drugs under Medicare."
(citation and internal quotation marks omitted)).
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mainly for those drugs which are most likely to be essential in the
treatment of seniors' illnesses."'" Nevertheless, no proposal for Medi-
care drug benefits survived due to congressional inaction, related
costs, and industry rebellion.6 2 Although Medicare did not offer out-
patient prescription drug coverage, Medicaid did so as an optional
benefit, which all states chose to offer in introducing their Medicaid
programs.63
The 1972 Social Security Act amendments fueled renewed interest
in a Medicare prescription drug benefit, but again no legislation
resulted. 64 However, these amendments, which became effective in
1973, included Medicare coverage for kidney transplantation and dial-
ysis. 65 Specifically, the federal government began paying for dialysis
and kidney transplantation for most Americans with ESRD,66 and any-
one who was diagnosed with ESRD automatically qualified for Medi-
care, irrespective of age or disability.67 Medicare entitlement, however,
was limited to one year following a successful transplant.68 The legisla-
tion was passed with the thought that the ESRD program would "bring
great social value at a modest cost" and that implementation of a
national health insurance program would occur within one to two
years. 69 National health insurance did not become a reality, and still
has not although the United States is closer to implementing one, but
this legislation saved the lives of over one million people who benefited
from renal replacement therapy. 70 Prior to this legislation, hospitals
would decide who would receive dialysis; those not selected-fre-
quently seniors, women, and blacks-were simply left to die of renal
61. Id. at 294 (citation omitted).
62. Robin J. Strongin, Providing Outpatient Prescription Drugs Through Medicare:
Can We Afford to? Can We Afford Not to?, NAT'L HEALTH POL'Y F., Mar. 1999, at 2,
available at http://www.nhpforg/pdfs-bp/BP-MedcareOutptRx 3-99.pdf.
63. Oliver et al., supra note 58, at 291.
64. Stephen H. Long, Prescription Drugs and the Elderly: Issues and Options, 13
HEALTH AFF. 158 (1994).
65. See Blumstein, supra note 37, at 7; Allen R. Nissenson & Richard A. Rettig,
Medicare's End Stage Renal Disease Program: Current Status and Future Prospects, 18
HEALTH AFF. 161 (1999).
66. Dooley & Gaston, supra note 41, at 709.
67. See Jonathan Himmelfarb & Glenn M. Chertow, Medicare ESRD Prospective
Payment System: Weighing the Evidence, 16 J. AM. Soc'y NEPHROLOGY 1164, 1164-65
(2005), available at http://jasn.asnjournals.org.cgi/reprint/16/5/1164.pdf.
68. See Eggers, supra note 38, at 56.
69. Himmelfarb & Chertow, supra note 67, at 1164.
70. See Eggers, supra note 38, at 55.
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failure. 71 Thus, there was great social value in providing renal replace-
ment therapy, 72 but at a larger than expected financial cost.73
When this Medicare ESRD program began in 1973, transplanta-
tion-considered the rarer and riskier procedure at that time-was
deemed to be a bridge therapy during gaps of dialysis74 as a result of
low graft survival rates.75 It was evident even then (some thirty years
ago), that because of the low graft survival rates lifetime immunosup-
pressive drug therapy was needed to ensure that the patient's immune
system did not reject the "new" kidney.76
By 1978, however, annual Medicare ERSD costs were nearing one
billion dollars-well more than expected-and projected costs were
estimated to be about triple those figures.77 Thus, in 1978, leaving
intact the basic entitlement portions of the 1972 legislation, Congress
responded by passing the ESRD Program Amendment, extending
Medicare entitlement following a successful transplant from one year
to three years. 78 This amendment was to encourage home dialysis and
71. Id. at 57 (reporting that of all persons chosen for dialysis treatment prior to the
1972 legislation, 75% were male, 91% were white, and only 7% were over the age of
55; but by 1978, 50% were female, 35% were black, and 46% were age 55 and older).
72. Id. at 56 (reporting that Medicare's ESRD Program generally achieved the
intended goal of ensuring access to life sustaining care for many people who would
not have received care).
73. MANAGEMENT OF TECHNOLOGY: THE KEY TO PROSPERITY IN THE THIRD MILLENNIUM
499 (Tarek M. Khalil et al. eds., 2001) (stating that estimated costs for the ESRD
Program for the initial year were between $35 million and $75 million, but that actual
costs came to $240 million and have increased yearly at an annual rate of twenty
percent).
74. EXTENDING MEDICARE COVERAGE, supra note 45, at 100 (explaining that
transplantation was still considered to be rare and risky at the time, and that dialysis
was the more fully developed treatment option); Eggers, supra note 38, at 56; see also
Robert S. Gaston & Carlton J. Young, African Americans and Renal Transplantation:
Disproportionate Need, Limited Access, and Impaired Outcomes, 323 AM. J. MED. SCI. 94,
95 (2002), available at http://www.amjmedsci.com/pt/re/ajms/pdfhandler.
00000441-200202000-00007.pdf (noting that thirty years ago, dialysis-not
transplantation-was deemed the optimal treatment for chronic renal failure).
75. A "graft" is an organ or tissue that is removed from one person and
transplanted into another person. "Graft survival rate" is the percentage of patients
who have functioning organs that were transplanted from another at a certain point in
time, usually measured in one, three, and five-year time frames. LIVER TRANSPLANT
PROGRAM, UNIV. Hosp. OF CINCINNATI, TERMS TO KNOW, http://www.cincinnati
transplant.org/about-glossary.htm (last visited Mar. 19, 2009).
76. EXTENDING MEDICARE COVERAGE, supra note 45, at 105; Eggers, supra note 38, at
56.
77. THE ROLE OF NUTRITION, supra note 34, at 311-12.
78. Eggers, supra note 38, at 56.
344 [Vol. 31:333
12
Campbell Law Review, Vol. 31, Iss. 2 [2009], Art. 4
http://scholarship.law.campbell.edu/clr/vol31/iss2/4
KIDNEY TRANSPLANTATION
kidney transplantation. 79 Because patients remained disabled or met
the Medicare age requirements, many patients remained on Medicare
after three years.8 ° This legislation provided Medicare coverage, but
outpatient immunosuppressive medications were not addressed."'
In the late 1970s, cyclosporine, an immunosuppressive drug, was
introduced with great success, changing the entire landscape of organ
transplantation.8 2 But cyclosporine was so expensive that post-trans-
plant immunosuppressive drug therapy became an issue.83 Because it
was administered as an outpatient drug, and therefore not reimburs-
able by Medicare, many patients declined the immunosuppression
regime prescribed by their physicians.84
In 1983, the Food and Drug Administration (the FDA) approved
cyclosporine, and it was introduced to the public in 1984.85 This FDA
approval was a major medical advance in transplantation medicine that
led to an increase in demand for organ transplants.8 6
Also in 1983, Dr. H. Barry Jacobs attempted to form a company
that would purchase kidneys from healthy, but very poor citizens of
Third World countries and sell them to wealthy American recipients.
8 7
Specifically, his proposal included creating the International Kidney
Exchange Limited, in which an indigent Third World resident would
set a price for a kidney, which Jacobs would then sell and collect a
brokerage fee. 8 Americans were outraged by Dr. Jacobs' proposal,8 9
79. Richard A. Rettig, Government's Role in Organ Transplantation Policy, in ORGAN
TRANSPLANTATION POLICY: ISSUES AND PROSPECTS, supra note 37, at 191, 195.
80. Eggers, supra note 38, at 56.
81. THE ROLE OF NUTRITION, supra note 34, at 312.
82. Rettig, supra note 79, at 193 ("The clinical experience of transplantation was
altered markedly by the introduction of cyclosporine into general use."); Rager, supra
note 33, at 18 ("Cyclosporine dramatically changed the course of organ
transplantation.").
83. THE ROLE OF NUTRITION, supra note 34, at 313; Oliver et al., supra note 58, at
291.
84. Rettig, supra note 79, at 193.
85. Eggers, supra note 38, at 57.
86. Margaret R. Sobota, Note, The Price of Life: $50,000 for an Egg, Why Not $1,500
for a Kidney? An Argument to Establish a Market for Organ Procurement Similar to the
Current Market for Human Egg Procurement, 82 WASH. U. L.Q. 1225, 1226 (2004).
87. Banks, supra note 4, at 72; Steve P. Calandrillo, Cash for Kidneys? Utilizing
Incentives to End America's Organ Shortage, 13 GEO. MASON L. REV. 69, 79-80 (2004);
Samuel Gorovitz, Is Law the Prescription That Can Cure Medicine?, 11 J.L. & HEALTH 1,
9 (1996).
88. Shelby E. Robinson, Organs for Sale? An Analysis of Proposed Systems for
Compensating Organ Providers, 70 U. COLO. L. REV. 1019, 1036 (1999) (citing Susan
Hankin Denise, Regulating the Sale of Human Organs, 71 VA. L. REV. 1015, 1021
(1985)).
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yet wealthy Americans engaged in this transplant tourism then and still
do today. 90 As a result, Congress passed the National Organ Trans-
plant Act of 1984 (NOTA),91 which banned the sale or purchase of
human organs for use in human transplantation.92
As originally proposed, NOTA provided coverage for
cyclosporine. 93 But due to funding concerns, President Ronald Rea-
gan signed the legislation, and NOTA became law in 1984 absent
cyclosporine coverage. 94 This was partly because the key supporters
of the legislation-United States Congressmen Gore, Kennedy, and
Waxman-were more concerned with the bill's central purpose (out-
lawing the sale or purchase of human organs) than the immunosup-
pressive drugs that are needed to maintain a kidney transplant. 95
Ultimately, after a political compromise, NOTA retained its core, but
funding for cyclosporine-an objectionable provision-fizzled out.96
Due to the rising costs of the Medicare ERSD program, the Omni-
bus Budget Reconciliation Act of 1981 was passed.97 It included the
Medicare secondary payer provision (the MSP), requiring beneficiaries
that maintained insurance other than Medicare to seek primary cover-
age from their private insurers before Medicare for the first twelve
months of coverage. 98 The twelve month period was extended to eigh-
teen months in 1990,99 and thirty months in 1997,1°° lessening the
federal government's financial burden.
89. Laura Meckler, Kidney Shortage Inspires a Radical Idea: Organ Sales, WALL ST. J.
ONLINE, Nov. 13, 2007, http://online.wsj.com/public/articleprint/
SB119490273908090431.html.
90. Press Release, Kathleen Maclay, UC Berkeley, UC Berkeley Anthropology
Professor Working on Organs Trafficking (Apr. 30, 2004), http://berkeley.edu/news/
media/releases/2004/04/30_organs.shtml.
91. 42 U.S.C. § 274e (2000).
92. Bethany J. Spielman, Acquiring and Allocating Human Organs for Transplant:
U.S. Law, in LEGAL PERSPECTIVES IN BIOETHICS 143, 146 (Ana S. Iltis et al. eds., 2008).
93. Keith J. Mueller, The National Organ Transplant Act of 1984: Congressional
Response to Changing Biotechnology, 8 REV. POL'Y RES. 346, 353 (1989).
94. Id.
95. Id. at 354; Blumstein, supra note 37 ("[T]he one explicitly mandatory
regulatory provision of the 1984 act was its ban on the purchase or sale of human
organs, as that would affect interstate commerce.").
96. Mueller, supra note 93, at 354.
97. Omnibus Budget Reconciliation Act of 1981, Pub. L. No. 97-35, § 2146, 95
Stat. 357, 783 (codified at 42 U.S.C. § 1395y).
98. See Eggers, supra note 38, at 57; Robert S. Lockridge, Jr., The Direction of End-
Stage Renal Disease Reimbursement in the United States, 17 SEMINARS IN DIALYSIS 125,
126 (2004).
99. Omnibus Budget Reconciliation Act of 1990, Pub. L. No. 101-508, § 4203, 104
Stat. 1388 (codified at 42 U.S.C. § 13 9 5y); Lockridge, supra note 98, at 126.
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Then, there was a medical breakthrough, albeit limited, allowing
access to immunosuppressive medications. Congress passed the
Omnibus Budget Reconciliation Act of 1986, covering eighty percent
of a Medicare recipient's immunosuppressive drug costs for up to one
year after a Medicare-covered kidney transplant' 01-which Congress
then amended in the Omnibus Budget Reconciliation Act of 1987,
enlarging the coverage from solely "immunosuppressive drugs" to
include "prescription drugs used in immunosuppressive therapy." 102
Still concerned about the lack of an outpatient prescription drug
benefit, Congress passed the Medicare Catastrophic Coverage Act of
1988 (MCCA), which provided prescription drug coverage for the sec-
ond year and beyond after a successful Medicare transplant.' 0 3 Under
MCCA, Medicare covered eighty percent of medication costs after the
beneficiary paid a $600 deductible.' 0 4 However, the proposed financ-
ing scheme for MCCA required seniors with higher incomes to pay the
lion's share.' 5 This was unacceptable and caused public outrage;
therefore, MCCA was repealed in 1989 before it could be
implemented. 10
6
In 1993, President William Clinton advanced the Health Security
Act (HSA), 107 which had a comprehensive benefit package.' 08 HSA
included prescription drugs, outpatient diagnostic testing and rehabili-
tation services, physician and hospital care, preventive services,
100. Balanced Budget Act of 1997, Pub. L. No. 105-33, § 4631, 111 Stat. 251, 486
(codified at 42 U.S.C. § 1395y); Lockridge, supra note 98, at 126.
101. Lockridge, supra note 98, at 126; Eugene Yen et al., Cost-Effectiveness of
Extending Medicare Coverage of Immunosuppressive Medications to the Life of a Kidney
Transplant, 4 AM. J. OF TRANSPLANTATION 1703 (2004).
102. Medicare Program; Medicare Coverage of Prescription Drugs Used in
Immunosuppressive Therapy, 60 Fed. Reg. 8951 (Feb. 16, 1995) (to be codified at 42
C.F.R. pt. 410).
103. Medicare Catastrophic Coverage Act of 1988, Pub. L. No. 100-360, § 202, 102
Stat. 683 (codified as amended at 42 U.S.C. § 1395x).
104. Oliver et al., supra note 58, at 298.
105. Id. at 299.
106. Thomas Rice et al., The Medicare Catastrophic Coverage Act: A Post-Mortem, 9
HEALTH AFF. 75, 76 (1990). But see Obama Calls for Overhaul of U.S. Health Care
System, CNN, Mar. 5, 2009, http://www.cnn.com/2009/POLITICS/03/05/health.
care.summit/index.html (reporting that in President Barack Obama's proposed health
care overhaul, he would mandate that "senior citizens making more than $170,000
annually to pay a greater share of their prescription drug costs under Medicare").
107. See Health Security Act, H.R. 3600, 103d Cong. (1993), available at http://
fr webgate.access.gpo.gov.cgi-bin/getdoc.cgi?dbname=I03-cong-b ills& d oc
id =
f:h3600ih.txt.pdf.
108. H. Richard Beresford, The Health Security Act: Coercion and Distrust for the
Market, 79 CORNELL L. REv. 1405, 1410 (1994).
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mental health and substance abuse services, family planning, and hos-
pice and home health care.'0 9 In particular, the Clinton administra-
tion noted that with the inclusion of prescription drug coverage,
Medicare would be the largest purchaser of prescription drugs and
would use its negotiating power to obtain price reductions from the
pharmaceutical companies. 11 After losing public support due to
attacks by conservatives and interest groups-claiming that the propo-
sal was too complicated, would restrict health care, and represented
too much government-the plan and other major health reform pro-
posals lost steam and died in September 1994.111
Meanwhile, the Omnibus Budget Reconciliation Act of 1993112
gradually phased in additional immunosuppressive medication cover-
age for patients who received a Medicare-covered transplant. 113 It
increased from twelve months to eighteen months in 1995, twenty-four
months in 1996, thirty months in 1997, and thirty-six months for
every Medicare transplant thereafter.1 14
Congress then passed the Balanced Budget Refinement Act of
1999.11' This legislation extended Medicare immunosuppressive drug
coverage for eight months for those whose coverage would otherwise
expire for a period of five years." 16
Following the aforementioned Acts, Congress then enacted the
Beneficiary Improvement and Protection Act of 2000 (BIPA), 1 17 which
provided lifetime immunosuppressive drug coverage to beneficiaries
who qualified for Medicare coverage because of age or disability. 118
But ESRD patients who have had a successful kidney transplant are no
longer considered disabled because transplantation is considered reha-
bilitation, thereby presumably allowing patients to go back to work.' 19
109. H.R. 3600.
110. Oliver et al., supra note 58, at 301-02.
111. Id. at 302.
112. See Omnibus Budget Reconciliation Act of 1993, Pub. L. No. 103-66, 107 Stat.
312.
113. See Lockridge, supra note 98, at 126.
114. Id.; HEALTH CARE FINANCING ADMINISTRATION, HCFA LEGISLATIVE SUMMARY: THE
OMNIBUS BUDGET RECONCILIATION ACT OF 1993, at 43 (1993), available at http://www.
cms.hhs.gov/relevantlaws/downloads/legislativesummaryforobraofl993.pdf.
115. Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999, Pub.
L. No. 106-113, § 227, 113 Stat. 1501.
116. Lockridge, supra note 98, at 126-27; Press Release, White House, Balanced
Budget Refinement Act of 1999: Highlights (Nov. 18, 1999), available at www.hhs.gov/
news/press/1999pres/19991118b.html.
117. Pub. L. No. 106-554, 114 Stat. 2763.
118. Gordon, supra note 9, at 1055; Yen et al., supra note 101.
119. Gordon, supra note 9, at 1055.
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Thus, unless ESRD patients continue to qualify for Medicare due to age
or disability, their immunosuppression therapy ends three years after
the transplant. Even though most kidney transplant patients suffer
from a number of physical limitations and symptoms that limit the
type and amount of work they can do,120 they no longer qualify for
lifetime immunosuppression drug therapy. As a result, they will have
to pay the annual costs of the anti-rejection drugs, which many people
of lesser financial means cannot afford because of the high cost of the
drugs.12' Thus, the current law pays for a lifetime of immunosuppres-
sive drugs for those who continue to qualify for Medicare, but not to
those younger than sixty-five or who are not otherwise disabled. Seem-
ingly, then, there is not equal access to kidney transplantation.
22
For years Congress was unsuccessful in trying to pass prescription
drug coverage for seniors, 123 but in 2003 President George W. Bush
signed into law the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (Medicare Modernization Act or the
MMA). 124 This was considered the most sweeping health care reform
legislation since the 1965 passage of Medicare and Medicaid.1
25
Although there were several attempts for an outpatient prescription
drug benefit since Medicare's enactment, the MMA was the first pre-
scription drug benefit for seniors and persons with disabilities.
126
This act was principally enacted presumably to cure the lack of Medi-
care coverage for outpatient prescription medications.
127
In particular, President Bush and Congress stated their concern
over the inability of senior citizens to afford prescription medica-
120. Id.
121. EXTENDING MEDICARE COVERAGE, supra note 45, at 113 (reporting that costs may
be as low as $5900 to more than $16,000 per year depending upon the regime that the
patient needs); Kasiske et al., supra note 9, at 2446 (reporting that annual costs for
immunosuppressive drug therapy may be as much as $10,000 to $14,000 for kidney
transplant recipients); Yen et al., supra note 101 (reporting the annual cost of
immunosuppressive medications to be between $5000 to $13,000).
122. Gordon, supra note 9, at 1055 ("This disproportionate coverage (based on
disability) calls into question the meaning of entitlement or equity in treatment
regardless of financial capacity.").
123. K. Shane Keene & Randy L. Byington, Weighing in on the Medicare Prescription
Drug Benefit Plan, 4 INTERNET J. HEALTHCARE ADMIN., No. 2 (2007), http://www.ispub.
com/ostia/index.php?xmlFilePath=journals/ijhca/vol4n2/drug.xml
124. Pub. L. No. 108-173, 117 Stat. 2066.
125. Keene & Byington, supra note 123.
126. William P. Bro, Importation of Prescription Drugs and Risks to Patient Safety, 36
CAL. W. INT'L LJ. 105, 107 (2005).
127. Thomas R. Barker, The Low-Income Subsidy in the New Medicare Drug Benefit, 1
J. HEALTH & BIOMEDICAL L. 49, 49 (2005).
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tions.' 28 The MMA's drug benefit, the focal point of the law, took
effect in January 2006.129 Even with the MMA, those kidney recipients
who no longer qualify for Medicare remain vulnerable to high medical
costs. Further, the MMA banned direct government negotiation with
drug manufacturers for lower drug prices,13°-the very opposite of
what the Clinton administration tried to accomplish with the advance-
ment of the HSA.' 3 ' This ban prompted the Democrats to introduce
the Medicare Fair Prescription Drug Price Act of 2007, currently
before the Senate, which would allow the government to negotiate
lower drug prices with drug manufacturers. 132
The benefits of the MMA are controversial. Some argue that it was
a political move by the Republican Party to garner votes from senior
citizens, but that both major political parties profited;' 33 others found
that the MMA provides elusive benefits to seniors and windfalls to the
drug manufacturers and insurance companies. 134 What is clear is that
still more is needed.
Thus, there have been several Congressional bills for comprehen-
sive immunosuppressive drug therapy, 135 but no legislation has been
128. Id. at 49-50.
129. Robert B. Doherty, Assessing the New Medicare Prescription Drug Law, 141
ANNALS OF INTERNAL MED. 391, 391 (2004); John K. Iglehart, The New Medicare
Prescription-Drug Benefit- a Pure Power Play, 350 NEW ENG. J. MED. 826, 827 (2004).
130. LAUREN HUTCHENS, THE HEALTH POLICY LANDSCAPE: 2001 AND BEYOND 8 (2007),
available at http://www.forumsinstitute.org/publs/nj/april-07.pdf
131. Health Security Act, H.R. 3600, 103d Cong. (1993), available at http://
frwebgate.access.gpo.gov.cgi-bin/getdoc.cgi?dbname= 103_cong-bills&docid=
f:h3600ih.txt.pdf.
132. S. 3, 110th Cong. § 2.
133. See Richard L. Hall & Robert P. Van Houweling, Campaign Contributions and
Lobbying on the Medicare Modernization Act of 2003, at 4 (May 30, 2006), http://
www.allacademic.com//meta/p-mla-apa-research-citation/1/5/0/4/6/pagesl5O
461/p150461-1.php.
134. See Melissa Ganz, The Medicare Prescription Drug Act of 2003: Are We Playing
the Lottery With Healthcare Reform?, 2004 DUKE L. & TECH REV. 0011 (2004), available
at http://www.law.duke.edu/journals/dltr/articles/2004ditroo 11.html.
135. See, e.g., Comprehensive Immunosuppressive Drug Coverage for Transplant
Patients Act, S. 173, 109th Cong. (2005); Comprehensive Immunosuppressive Drug
Coverage for Transplant Patients Act, H.R. 2051, 109th Cong. (2005); Comprehensive
Immunosuppressive Drug Coverage for Transplant Patients Act, S. 178, 108th Cong.
(2003); Comprehensive Immunosuppressive Drug Coverage for Transplant Patients
Act, H.R. 2223, 108th Cong. (2003); Comprehensive Immunosuppressive Drug
Coverage for Transplant Patients Act, S. 1204, 107th Cong. (2001); Comprehensive
Immunosuppressive Drug Coverage for Transplant Patients Act, S. 2399, 106th Cong.
(2000); Comprehensive Immunosuppressive Drug Coverage for Transplant Patients
Act, H.R. 5276, 106th Cong. (2000); Immunosuppressive Drugs Coverage Act, S. 631,
350
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enacted. This brings us to where we are today: the Transplant Drug Act
before the Senate. 136 The bill was introduced on August 1, 2007 and
remains in the embryonic stages of the legislative process. 137 But
would passage of the Transplant Drug Act make a difference?
B. Would Legislative Changes Make a Difference?
Immunosuppressive drug therapy is the most significant health
care expense after the three year post-transplant.' 38 It has swiftly
developed "as a major health care issue with implications for chronic
rejection and graft loss.' 39 Chronic rejection is known as "any form
of nonspecific late graft dysfunction[,] 4"'4 and is "the leading cause of
late graft failure in renal transplant recipients."' 4 ' Because of the cost
of immunosuppressive medications, many fail to comply with their
post-transplant medical regimen. 142  Noncompliance with immu-
nosuppressive drug therapy for kidney transplants is the third leading
cause of graft lOSS.143 Patients who are noncompliant with their immu-
nosuppressive drug therapy lose their transplants or die at rates much
greater than patients who comply. 144 Thus, medical compliance after
a kidney transplant is critical to the maintenance of the transplanted
kidney and the patient's life.
145
106th Cong. (1999); Immunosuppressive Drug Coverage Extension Act, H.R. 1115,
106th Cong. (1999).
136. S. 2320, 110th Cong. (2007).
137. Id.
138. Willoughby et al., supra note 17, at 128.
139. Jindel et al., supra note 42, at 2868.
140. Winsett et al., supra note 23, at 19, 21; see also Phillip F. Halloran,
Immunosuppressive Drugs for Kidney Transplantation, 351 NEw ENG. J. MED. 2715
(2004) ("The central issue in organ transplantation remains suppression of allograft
rejection. Thus development of immunosuppressive drugs is the key to successful
allograft function.").
141. R.B. Isaacs et al., Noncompliance in Living-Related Donor Renal Transplantation:
The United Network of Organ Sharing Experience, 31 TRANSPLANTATION PROCEEDINGS
19S (1999).
142. Yen et al., supra note 101, at 1707.
143. B. Siegal & S.M. Greenstein, Profiles of Noncompliance in Patients with a
Functioning Renal Transplant: A Multicenter Study, 31 TRANSPLANTATION PROCEEDINGS
1326, 1326 (1999); see also Chisolm et al., supra note 45, at 1775 ("Nonadherence to
[immunosuppressant therapy] after transplantation is one of the leading causes of
allograft rejection, graft loss, and death.").
144. Yen et al., supra note 101, at 1703.
145. Antonio Giuffrida & David Torgerson, Should We Pay the Patient? Review of
Financial Incentives to Enhance Patient Compliance, 315 BRIT. MED. J. 703, 703 (1997)
("Compliance can be defined as the extent to which a patient's behavior coincides with
medical advice.").
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This is important because current Medicare law only allows for
immunosuppressive drug therapy for a limited time post-transplant for
individuals who no longer qualify for Medicare. 146 Thereafter, those
individuals have to pay for the immunosuppressive drug therapy them-
selves, or with the assistance of others. 147 This is often difficult for
those in low-income brackets, as shown by the case studies of Jessica
and Emily.' 4 ' "The inability to afford immunosuppressive agents is
thought to underlie as many as half of all [noncompliance] cases."'149
Thus, there is a direct correlation between lack of Medicare-sponsored
immunosuppressive medication and noncompliance.
Health professionals have studied the effect of extending coverage
of immunosuppressive medications by Medicare for kidney transplants
in a variety of settings. By and large, the studies have concluded that
Medicare's extension of coverage of immunosuppressive medications
would positively impact graft survival rates for low-income transplant
recipients. 150 In fact, the conclusion is that when there is equal access
to immunosuppressive medications, there are no differences in graft
survival rates for kidney transplant patients.15 1
One study evaluated the last two years in which Medicare paid for
immunosuppressive medication for only one year, 1992 to 1993, and
the first few years in which Medicare paid for three years of immu-
nosuppressive medication, 1995 to 1997.152 The study revealed the
following: "Low income did affect graft survival in the second and
third years post-transplant, but only during the period in which Medi-
care did not pay for immunosuppressant medications. ' 153 Thus, the
two year extension that Medicare granted post-1993 was critical to the
graft survival of those who could not afford to pay for the medications
after the end of the government's assistance with immunosuppressive
medications.
146. 42 U.S.C. § 1395 (2006).
147. See, e.g., Kasiske et al., supra note 9, at 2446.
148. See discussion supra Part 1.
149. Willoughby et al., supra note 17, at 127 (noting also that this noncompliance
may be partly a result of loss of or lack of health insurance coverage).
150. See, e.g., Robert S. Woodward et al., Effect of Extended Coverage of
Immunosuppressive Medications by Medicare on the Survival of Cadaveric Renal
Transplants, 1 AM. J. TRANSPLANTATION 69, 73 (2001); Yen et al., supra note 101, at
1707.
151. Woodward et al., supra note 150, at 73.
152. Id. at 70. The study only evaluated those patients who received first cadaveric
renal transplants and not patients who received living donor kidneys, multi-organ
transplants, or those who had a previous transplant.
153. Id.
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Based on the results of this study, another group of health profes-
sionals conducted a separate study "to estimate the expected economic
and clinical effects of extending Medicare immunosuppressive cover-
age availability from three years to the life of the transplanted kid-
ney.' 5 4  This study revealed that extending Medicare
immunosuppressive coverage for a lifetime will result in societal sav-
ings as well as reduced risks of transplant failure and death in those
who cannot afford to pay the cost of the immunosuppressive medica-
tions-those with low incomes.
155
Another study revealed that patients who were most likely not to
comply with the immunosuppressant regime were younger, female,
single, and non-white, 156 but these are generally the very same individ-
uals who make up the low-income population. 157 Moreover, workers
in low-income families have more health problems than workers in
middle-income families.' 58 Therefore, it is not surprising that non-
compliance is directly correlated to the inability to afford the immu-
nosuppressive drug therapy. In sum, a lifetime of immunosuppressive
drug therapy would have an equally positive impact in kidney trans-
plantation even amongst people with varied incomes.
C. What Would this Legislative Change Mean?
1. For the Kidney Recipient
Immunosuppressive drug therapy is the most daunting cost for
the kidney recipient. 159 However, patients may obtain help in paying
for these expensive medications. For example, such assistance may
come from employer-sponsored health insurance, private insurance
(Medigap insurance, for example), Medicare, Medicaid, charitable
organizations, family, or pharmaceutical company assistance pro-
grams.' 60 Yet, these varying methods of assistance are not guaranteed,
are usually for a short term only, and often have income-limits tied to
154. Yen et al., supra note 101, at 1704.
155. Id. at 1707.
156. Chisholm et al., supra note 45, at 1776 (noting that noncompliance is more
common amongst blacks, Hispanics, younger adults, singles, and those who have had
their transplants for a longer time and that low income patients were less compliant
than patients in higher socioeconomic groups); Jindel et al., supra note 42, at 2871.
157. See GREGORY Acs & PAMELA LOPREST, URBAN INST., WHO ARE LOW-INCOME
WORKING FAMILIES? 4-6 (2005), available at http://www.urban.org/UploadedPDF/
311242_workingjfamilies.pdf (describing low income families as comprising younger
adults, minorities and single parents).
158. Id. at 6.
159. See Kasiske et al., supra note 9.
160. Id. at 2446-47; see also Chisholm et al., supra note 45, at 1780.
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them as well as an application process.16' Most troubling, when Con-
gress passed BIPA in 2000, some pharmaceutical companies termi-
nated their assistance programs for Medicare beneficiaries because the
government extended its coverage for the immunosuppressive medica-
tions. 112 This means less help for those who need the most help.
In addition to the yearly costs of the anti-rejection medications,
there are other costs associated with kidney transplants that are often
overlooked. Patients, even those with sufficient health insurance cover-
age, may also have to pay for transportation, housing, and food for
evaluation or follow up visits to the transplant centers; costs for time
away from work for them and their family members; insurance premi-
ums; deductibles; and co-payments. 163 Patients may also require other
outpatient medications, such as antihypertensive agents and antibiot-
ics for infections, which Medicare does not cover.' 64 Thus, passage of
the Transplant Act would reduce, but not eliminate, the financial and
emotional burdens of kidney recipients, improve patient access, and
improve compliance with the immunosuppression regimen.' 65 This
would then reduce loss of the transplanted kidney, thereby reducing
Medicare spending for re-transplantation or dialysis.' 66
2. For the Federal Government
Congress engaged the Institute of Medicine (10M) on a few occa-
sions to evaluate the ESRD program and the feasibility of extending the
strict time limitations for immunosuppressive drug therapy. 167 1GM
recommended more than once that Congress eliminate the three year
limit.168
In 1987, IOM recommended that "Congress eliminate the three-
year limit on Medicare eligibility for ESRD patients who are successful
transplant recipients and authorize an entitlement equal to that of
ESRD patients who are treated by dialysis.' 1 69 Congress responded by
161. Kasiske et al., supra note 9, at 2446-47.
162. Marie A. Chisholm, Increasing Transplant Patients' Access to Medications:
Medicare and Beyond, 58 AM. J. HEALTH-SYS. PHARMACY 2081 (2001).
163. Kasiske et al., supra note 9, at 2446.
164. EXTENDING MEDICARE COVERAGE, supra note 45.
165. Id. at 22.
166. Id.
167. Kasiske et al., supra note 9, at 2446 (referring to a 1987 IOM study to evaluate
the ESRD program and a 1997 study to evaluate the extension of immunosuppressant
drugs beyond three years).
168. Id.
169. Id.
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extending immunosuppressive drug coverage from one to three
years. 170
Then, in 1997, Congress requested that 10M study the issue of
further extending immunosuppressive drug therapy beyond the three
years.' 7 ' Two years later, Congress extended the three-year time limit
temporarily for another eight months under very limited guidelines.
172
Ultimately, this three-year limit was extended for a lifetime, but only
for those who continue to qualify for Medicare due to age or disabil-
ity.173 But what about the others like Jessica and Emily who may no
longer qualify for Medicare after transplantation?
The main reason that lifetime immunosuppressive therapy has not
been granted to all patients qualifying under the ESRD program (irre-
spective of age or disability) is because of the estimated costs of such
an entitlement. 74 But several years ago, 10M engaged a research
group to study the estimated costs of such entitlement, and the conclu-
sion was that a savings would result because the accessibility of immu-
nosuppressive drug therapy would reduce the kidney allograft failure
rate.17 5 This study, of course, assumed some variables not currently
in play. For example, the study assumed, amongst other variables,
that: the MSP requirement would extend from thirty months to an
indefinite period, thus reducing by twenty-five percent the number of
patients who would burden Medicare; that the annual cost of immu-
nosuppressive drug therapy in 2000 would be $5400 with a yearly
increase of four percent; and that the cost would include a twenty per-
cent co-payment and a five percent wholesale discount.' 76 Thus, this
resulted in an estimated cost savings of over $500 million. 17 7 Another
study with present day variables would be beneficial, but nevertheless,
it appears that the end result would be a savings to the government.
In addition, for the past several years, Congress has considered
several drug bills, often in several iterations, but most of them have
170. Budget Reconciliation Act of 1993, Pub. L. No. 103-66, 107 Stat. 312.
171. Kasiske et al., supra note 9, at 2446.
172. See supra notes 113-14 and accompanying text.
173. See supra notes 115-16 and accompanying text.
174. Kasiske et al., supra note 9 (noting that the question of how to pay for
immunosuppressive drug therapy, the key to the success to organ transplantation, has
plagued Congress for many years).
175. Id. at 2448 (emphasis added).
176. Id.
177. Id. at 2449; see also Yen et al., supra note 101 (calculating an expected
discounted savings to society from lifetime coverage of $136 million annually).
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failed. 178 There are a handful of other bills presently under considera-
tion that impact prescription drugs: Pharmaceutical Market Access
and Drug Safety Act of 2007,1'9 Pharmaceutical Market Access Act of
2007,180 Medicare Fair Prescription Drug Price Act of 2007, l and
Prescription Drug Affordability Act of 2007.112 Although passage of
these bills will not solve America's health care crises, they will allow
greater access to cheaper drugs for the American people.
Prescription drugs are one of the fastest growing costs in the
health care industry.' 83 America can expect some immediate and
sweeping changes because President Barack Obama supports access to
cheaper drugs for Americans. For example, President Obama believes
that the ban on allowing Medicare to directly negotiate with drug com-
panies for cheaper drugs should be repealed.' 84 Such a bill is pres-
ently pending before Congress in the Medicare Fair Prescription Drug
Price Act of 2007.185 He also supports allowing importation of pre-
scription drugs to the United States.' 86 The same drugs sold in the
United States are often sold for about sixty percent less in foreign
countries, such as Canada and those in Europe. 187 Finally, President
Obama advocates the use of generic drugs when available and would
prevent the major drug companies from paying generic drug compa-
nies from introducing their products to the market so that the brand
name drug companies can continue to charge exorbitant prices for
drugs.' 8 In the first few weeks of his administration, President
Obama called for an overhaul of the United States health care system,
178. See, e.g., Medicare Prescription Drug Price Negotiation Act of 2007, H.R. 4,
110th Cong.; Prescription Drug Affordability Act, H.R. 194, 110th Cong. (2007);
Medicare Prescription Drug Price Reduction Act, S. 445, 109th Cong. (2005); Safe
IMPORT Act of 2004, S. 2493, 108th Cong.; Pharmaceutical Freedom Act of 2000,
H.R. 3636, 106th Cong.
179. Pharmaceutical Market Access and Drug Safety Act of 2007, S. 242, 110th
Cong.
180. Pharmaceutical Market Access Act of 2007, S. 251, 110th Cong.
181. Medicare Fair Prescription Drug Price Act of 2007, S. 3, 110th Cong.
182. H.R. 194.
183. KAREN DAVIS ET AL., SLOWING THE GROWTH OF U.S. HEALTH CARE EXPENDITURES:
WHAT ARE THE OPTIONS? 4 (2007).
184. BarackObama.com, Barack Obama and Joe Biden's Plan to Lower Health Care
Costs and Ensure Affordable, Accessible Health Coverage for All, http://www.
barackobama.com/pdf/issues/HealthCareFullPlan.pdf (last visited Jan. 2, 2009).
185. S. 251.
186. BarackObama.com, supra note 184.
187. PATENTED MED. PRICES REVIEW BD., ANNUAL REPORT 9 (2002).
188. BarackObama.com, supra note 184.
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including a reform of our country's prescription drug policies.18 9 This
is because America's health care system is broken as a whole, and in
particular with respect to life-saving prescription drugs for kidney
transplantation.
III. RECOMMENDATIONS
Immunosuppressive medications should be provided by the fed-
eral government for people who cannot afford them. Passage of the
Transplant Drug Act is a good start, and this would have a significant
impact on those who would not qualify for Medicare after the three
year limit (like Emily), and thus, would have to pay the full amount for
immunosuppressive medications.
However, more is needed. Individuals in Jessica's position, who
may continue to qualify for Medicare due to age or disability, are una-
ble to pay the co-payments and deductibles for the immunosuppressive
medications.' 90 These are often the individuals who have fixed
incomes, like a monthly disability check. Thus, Medicare should cover
100% of the cost of immunosuppressive medications, not just eighty
percent, as the current Transplant Drug Act pending before the Senate
provides.
Prior bills to eliminate the three year time limitation have not
passed due to funding concerns,1 91 and elimination of the twenty per-
cent co-payments would undoubtedly increase funding concerns. Nev-
ertheless, elimination of the twenty percent contribution is critical as it
can "lead to nonadherence with the prescribed medication regime,
potential organ dysfunction, organ loss or even death."'192 Further,
when considering the costs of re-transplantation and dialysis, as com-
pared to organ transplant maintenance, Congress cannot afford to fail
to pass legislation funding the elimination of the three year time limita-
tion, and even the elimination of the twenty percent co-payments.
193
189. See Obama Calls for Overhaul of U.S. Health Care System, supra note 106.
190. Gordon, supra note 9, at 1053 (noting that co-payments for
immunosuppressive medications may range from $167 to $233 per month).
191. Bill Eliminating 3-Year Time Limitation on Medicare Coverage for Kidney
Transplants Introduced in Senate, TRANSPLANT NEWS, Dec. 2007, http://findarticles.
com/p/articles/mi_mOYUG/isJai n24241935 ("Legislation eliminating the three-
year time limitation on coverage has been introduced in previous congresses wit bi-
partisan support but there has never been enough money to fund it.").
192. NATCO, supra note 9.
193. GAO Study Finds Lifetime Immunosuppresant Drug Coverage Saves Money,
Improves Patient Outcomes, TRANSPLANT NEws, Nov. 2007, http://findarticles.com/p/
articles/mi mOYUG/isJai n27457827 (reporting that a failed transplant costs 500
percent more than maintenance of a functioning transplant).
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Elimination of the co-payments and deductibles is not without prece-
dent. In 1965, the SSA assisted seniors with premiums, deductibles,
co-payments and other uncovered costs.' 94
Jessica and Emily's problems also bring into focus something even
greater. Even with the passage of the Transplant Act, there is still much
to be desired in America's non-existent comprehensive health care cov-
erage for its citizens. Americans need universal health care. Indeed,
President Obama believes that "health care is a right for every Ameri-
can."'195 Americans can expect a significant overhaul to its current
health care system. 196
It is understandable that developing countries do not have univer-
sal health care, but the United States is the only industrialized country
without universal health care. 197 Yet, the United States has access to
more advanced medical care than many other countries. That is, in the
United States, the poor have very limited or no access to health care
and the wealthy have access to as much health care as they desire. This
disparity in health care directly impacts ESRD, and the number of peo-
ple suffering with ESRD is growing rapidly.' 98 The ESRD program was
passed with the understanding that a national health insurance pro-
gram was on the way; 199 but to date, Americans still lack universal
health care. The ESRD program was also passed in an effort to
encourage kidney transplants. 20 0  But without adequate funding to
ensure that those with ESRD can pay for the costly immunosuppres-
194. Almanac of Policy Issues, supra note 54; see also supra Part IL.A (stating that
Congress passed the SSA in 1965, which included "expansion of an existing program
to assist seniors with out of pocket costs, such as premiums, deductibles, co-payments,
and other uncovered costs").
195. Joe Klein, The Obama Surge: Will It Last?, TIME, Oct. 9, 2008, available at http:/
/www.time.com/time/politics/article/0,8599,1848518,00.html.
196. A Start on Health Care Reform, N.Y. TIMES, Mar. 7, 2009, available at http://
www.nytimes.com/2009/03/08/opinion/08sunl.html (stating that President Barack
Obama has committed to infusing $634 billion into health care reform over the next
ten years).
197. MaxwellJ. Mehlman, "Medicover": A Proposal for National Health Insurance, 17
HEALTH MATRIX 1, 3 (2007).
198. David Tuller, Kidney Disease Takes a Growing Toll, N.Y. TIMES, Nov. 17, 2008,
available at http://www.nytimes.com/2008/11/18/health/18kidneydisease.html?_r-
l&scp=2&sq=chronic+kidney+disease&st=nyt.
199. Nancy Kutner, Coverage and Cost: What Has a 30 Year American "Experiment
in National Healthcare" Shown? 2 (2005), http://www.allacademic.com//meta/p mla
.aparesearch-citation/0/2/1/8/0/pages21809/p 2 1809-1 .php.
200. Ctrs. for Medicare & Medicaid Servs., Overview ESRD (Jan. 27, 2009), http://
www.cms.hhs.gov/esrdgeneralinformation/.
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sive medications, kidney transplants remain an option primarily for
the well-to-do.
CONCLUSION
Transplant professionals are aggressively debating overturning the
ban of the sale of human organs in the United States, which would
presumably result in the rich legally purchasing organs from the
poor.2°1 But this would be absolute irony: If the United States over-
turns the ban on the purchase and sale of human organs, as many
transplant professionals are proposing, then the group of persons who
would be likely targets for selling their organs-poor people-would be
most likely not to financially qualify to be a kidney recipient in the
event they needed a kidney. There are a limited number of kidneys
and they are being doled out to those who can afford to maintain the
life of the kidney. Health care in America must be more accessible to
more people. And as one senator in favor of passage of one of the
earlier ESRD bills asked: "How do we explain that the difference
between life and death is a matter of dollars?"
20 2
201. See generally Jennifer M. Smith, "Dirty Pretty Things" and the Law: Curing the
Organ Shortage and Health Care Crises in America, 12 CHAP. L. REV. 361 (2009).
202. Lisa Raiz, The Transplant Trap: The Impact of Health Policy on Employment Status
Following Renal Transplantation, 8 J. HEALTH & SOC. POL'Y 67, 68 (1997) (quoting
Senator Vance Hartke).
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